Insider Selling: Biogen Inc (BIIB) EVP Sells 1,294 Shares of Stock

Biogen Inc (NASDAQ:BIIB) EVP Alfred Sandrock sold 1,294 shares of the stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $298.85, for a total transaction of $386,711.90. Following the transaction, the executive vice president now directly owns 7,296 shares in the company, valued at $2,180,409.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Alfred Sandrock also recently made the following trade(s):

  • On Tuesday, February 20th, Alfred Sandrock sold 743 shares of Biogen stock. The shares were sold at an average price of $292.00, for a total transaction of $216,956.00.

Biogen Inc (NASDAQ:BIIB) opened at $286.10 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.34. Biogen Inc has a 52 week low of $244.28 and a 52 week high of $370.57. The company has a market cap of $60,813.70, a PE ratio of 13.18, a price-to-earnings-growth ratio of 1.50 and a beta of 0.75.

Biogen (NASDAQ:BIIB) last issued its earnings results on Thursday, January 25th. The biotechnology company reported $5.26 EPS for the quarter, missing analysts’ consensus estimates of $5.44 by ($0.18). Biogen had a return on equity of 38.32% and a net margin of 20.69%. The firm had revenue of $3.31 billion for the quarter, compared to analysts’ expectations of $3.08 billion. During the same period last year, the firm earned $5.04 earnings per share. Biogen’s revenue for the quarter was up 15.1% on a year-over-year basis. equities analysts predict that Biogen Inc will post 24.88 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of BIIB. Exane Derivatives raised its stake in Biogen by 810.3% during the third quarter. Exane Derivatives now owns 710 shares of the biotechnology company’s stock worth $222,000 after purchasing an additional 632 shares during the period. Meeder Asset Management Inc. raised its stake in Biogen by 64.6% during the third quarter. Meeder Asset Management Inc. now owns 9,753 shares of the biotechnology company’s stock worth $3,054,000 after purchasing an additional 3,826 shares during the period. Tributary Capital Management LLC increased its position in shares of Biogen by 21.2% during the third quarter. Tributary Capital Management LLC now owns 2,000 shares of the biotechnology company’s stock valued at $626,000 after acquiring an additional 350 shares during the last quarter. Oakbrook Investments LLC increased its position in shares of Biogen by 321.2% during the third quarter. Oakbrook Investments LLC now owns 52,970 shares of the biotechnology company’s stock valued at $16,586,000 after acquiring an additional 40,395 shares during the last quarter. Finally, LS Investment Advisors LLC increased its position in shares of Biogen by 4.1% during the third quarter. LS Investment Advisors LLC now owns 6,545 shares of the biotechnology company’s stock valued at $2,049,000 after acquiring an additional 258 shares during the last quarter. 89.20% of the stock is currently owned by institutional investors.

Several equities analysts have issued reports on BIIB shares. HC Wainwright reaffirmed a “buy” rating and set a $363.00 price objective (up from $340.00) on shares of Biogen in a report on Friday, January 26th. Citigroup reaffirmed an “outperform” rating and set a $380.00 price objective (up from $350.00) on shares of Biogen in a report on Tuesday, January 16th. Mizuho set a $400.00 price objective on shares of Biogen and gave the company a “buy” rating in a report on Thursday, January 18th. Jefferies Group reaffirmed a “hold” rating on shares of Biogen in a report on Friday, January 26th. Finally, Oppenheimer set a $350.00 price objective on shares of Biogen and gave the company a “buy” rating in a report on Tuesday, November 28th. Ten research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company’s stock. Biogen has an average rating of “Buy” and a consensus price target of $368.99.

WARNING: “Insider Selling: Biogen Inc (BIIB) EVP Sells 1,294 Shares of Stock” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/22/insider-selling-biogen-inc-biib-evp-sells-1294-shares-of-stock.html.

About Biogen

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Insider Buying and Selling by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply